KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palvella Therapeutics (PVLA) Other Working Capital Changes: 2014-2024

Historic Other Working Capital Changes for Palvella Therapeutics (PVLA) over the last 11 years, with Dec 2024 value amounting to $1.3 million.

  • Palvella Therapeutics' Other Working Capital Changes rose 103.70% to $1.3 million in Q4 2024 from the same period last year, while for Dec 2024 it was $1.5 million, marking a year-over-year increase of 650.55%. This contributed to the annual value of $1.5 million for FY2024, which is 650.55% up from last year.
  • Palvella Therapeutics' Other Working Capital Changes amounted to $1.3 million in Q4 2024, which was up 840.30% from $134,000 recorded in Q3 2024.
  • In the past 5 years, Palvella Therapeutics' Other Working Capital Changes ranged from a high of $53.3 million in Q4 2021 and a low of -$47.6 million during Q4 2022.
  • Over the past 3 years, Palvella Therapeutics' median Other Working Capital Changes value was $307,000 (recorded in 2022), while the average stood at -$1.6 million.
  • As far as peak fluctuations go, Palvella Therapeutics' Other Working Capital Changes slumped by 739.54% in 2021, and later soared by 3,341.02% in 2023.
  • Quarterly analysis of 5 years shows Palvella Therapeutics' Other Working Capital Changes stood at -$29.3 million in 2020, then soared by 282.14% to $53.3 million in 2021, then slumped by 189.18% to -$47.6 million in 2022, then increased by 28.37% to -$34.1 million in 2023, then skyrocketed by 103.70% to $1.3 million in 2024.
  • Its Other Working Capital Changes was $1.3 million in Q4 2024, compared to $134,000 in Q3 2024 and $163,000 in Q2 2024.